Global Ultomiris Drug Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Ultomiris Drug Market was valued at $5.0 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 26.5% CAGR, to an estimated market size of $16.2 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The Global Ultomiris Drug Market encompasses the commercialization and therapeutic application of ravulizumab, a long-acting humanized monoclonal antibody and C5 complement inhibitor. It is primarily indicated for the treatment of rare, life-threatening complement-mediated disorders including Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), and Neuromyelitis Optica Spectrum Disorder (NMOSD).
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Ultomiris Drug Market in the period 2025-30:
- The transition from bi-weekly eculizumab to 8-week maintenance dosing with Ultomiris is the primary driver for patient retention and treatment compliance.
- Aggressive market conversion strategies are successfully migrating the majority of the existing Soliris patient base to the Ultomiris platform to protect franchise revenue.
- Rapid label expansion into neurology indications, particularly gMG, is currently the fastest-growing segment of the market.
- The development and adoption of subcutaneous formulations are expected to shift the site of care from hospitals to home-based self-administration.
- Emerging competition from oral complement inhibitors like Fabhalta is challenging the dominance of intravenous C5 inhibitors in the PNH segment.
- The introduction of eculizumab biosimilars is increasing payer pressure and may lead to stricter step-therapy requirements for new patient initiations.
- Improved diagnostic tools and biomarker testing are increasing the identification rates of ultra-rare complement-mediated diseases in emerging markets.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Generalized Myasthenia Gravis (gMG)
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Neuromyelitis Optica Spectrum Disorder (NMOSD)